MOTS-c

MOTS-c

MOTS-c is a 16-amino-acid peptide that your mitochondria actually make themselves, encoded inside the mitochondrial DNA rather than the nuclear genome. It's one of the only known peptides with this origin, and your body uses it as a signal that travels from your mitochondria out to the rest of the body to coordinate how you handle fuel. Most people inject it for the same reason they'd consider exercise: to improve insulin sensitivity, burn fat more efficiently, and restore some of the metabolic flexibility that drops off with age. It's been called an "exercise mimetic" because it activates a lot of the same pathways a hard workout does.
In a bodybuilding context MOTS-c is being have been used to improve fat loss and keep energy sustained during a heavy cut when caloric intake is restricted. The longevity community uses MOTS-c for keeping mitochondrial function up regulated for sufficient ATP synthesis and health purposes.
MOTS-c levels in your blood and muscle drop with age, and they drop further if you're sedentary, overweight, or insulin resistant. Endogenous MOTS-c also rises sharply during exercise, in one human study skeletal muscle MOTS-c jumped roughly 12-fold during cycling. The premise of injecting it is to top up a signal that's already declining and use it as an amplifier on top of training, especially if you're metabolically stuck or older. Without a metabolic challenge to act on, the metabolic effects (fat loss, insulin sensitization) are minimal.

Deep-dive

MOTS-c was discovered in 2015 by Changhan Lee and Pinchas Cohen at USC. The 16-amino-acid sequence (MRWQEMGYIFYPRKLR) is encoded inside the 12S rRNA region of the mitochondrial genome, which until then was thought to only encode components of the electron transport chain. Discovering that the mitochondrial genome also produces bioactive signaling peptides opened up an entirely new class of molecules called mitochondrial-derived peptides (MDPs), with MOTS-c and humanin being the two most studied.
MOTS-c is a stress-response signal from your mitochondria to the rest of your body. When mitochondria sense metabolic stress (low energy, exercise, fasting, oxidative load), they ramp up MOTS-c production. The peptide leaves the mitochondria, enters the cytoplasm, and either acts locally on AMPK or travels to the nucleus where it binds to antioxidant response elements and turns on stress-adaptation genes. It's basically how your mitochondria tell your nuclear DNA "we're under load, adjust accordingly." Without this signal, the nucleus has no real-time read on mitochondrial state.
Day-to-day functions of endogenous MOTS-c:
  • Glucose handling. Helps muscle take up glucose without needing as much insulin. Part of why exercise improves insulin sensitivity, the MOTS-c released during training is doing some of that work.
  • Fat oxidation. Keeps muscle and liver oriented toward burning fat for fuel rather than storing it. People with low MOTS-c have worse metabolic flexibility.
  • Mitochondrial quality control. Promotes mitochondrial biogenesis (making new mitochondria) and helps clear out damaged ones. This is part of why fit people have more, healthier mitochondria.
  • Stress adaptation. When you're cold, fasted, exercising, or under oxidative stress, MOTS-c upregulates antioxidant defenses and heat-shock proteins so the cell can handle the load.
  • Inflammation tone. Suppresses pro-inflammatory cytokines like IL-1β and IL-6 in adipose tissue. Low MOTS-c is associated with the chronic low-grade inflammation that comes with obesity and aging.
  • Bone maintenance. Acts on osteoblasts to support bone formation, which is part of why MOTS-c loss with age tracks with bone loss.
  • Reproductive signaling. Animal data shows MOTS-c reaches the hypothalamus and affects GnRH/LH/FSH/testosterone, suggesting it's part of how metabolic state communicates with the reproductive axis (your body downregulates fertility when energy is scarce, MOTS-c may be one of those signals).
MOTS-c primarily acts through the folate-AICAR-AMPK pathway. It disrupts the folate-methionine cycle, which causes a metabolic intermediate called AICAR to accumulate. AICAR is a potent activator of AMPK, the master metabolic switch that exercise also turns on. Once AMPK is activated downstream effects include GLUT4 transporters moving to muscle cell surfaces (pulling glucose into muscle without needing insulin), acetyl-CoA carboxylase getting phosphorylated (which clears the brake on fatty acid oxidation, so muscles start burning more fat), and hepatic glucose production gets suppressed. This is why MOTS-c improves insulin sensitivity independent of insulin signaling itself, it bypasses the receptor and works on the downstream machinery.
A 2024 Nature Communications paper showed MOTS-c also binds directly to casein kinase 2 (CK2), which appears to be how it differentially affects muscle versus fat. In muscle CK2 activity goes up, in fat it goes down. This explains why MOTS-c improves muscle quality and insulin sensitivity while simultaneously reducing fat mass.
MOTS-c also translocates to the cell nucleus under metabolic stress and directly regulates expression of stress-response genes with antioxidant response elements. So it's not just a metabolic activator, it's a retrograde signaling molecule that lets mitochondria talk back to the nuclear genome and shift adaptive gene expression in real time.
Insulin sensitivity and fat loss. This is the most replicated finding. In the original 2015 Cell Metabolism paper, MOTS-c reversed both diet-induced obesity and age-related insulin resistance in mice. A 2019 metabolomics paper showed MOTS-c reduces sphingolipid, monoacylglycerol, and dicarboxylate metabolism, all pathways that are upregulated in obese and type 2 diabetic models. In humans, circulating MOTS-c levels are inversely correlated with BMI, waist-to-hip ratio, fasting insulin, HOMA-IR, and HbA1c. The lower your MOTS-c, the worse your metabolic markers tend to be.
Exercise capacity and aging. Reynolds et al. (2021) in Nature Communications showed MOTS-c injections (5 mg/kg in mice) significantly improved running time and grip strength in young, middle-aged, and old mice. Old mice on MOTS-c roughly doubled their running time. The same paper showed exercise itself induces MOTS-c, with skeletal muscle MOTS-c rising 12-fold and circulating levels rising 50% during a single cycling session in healthy young men. A separate 2024 endurance training study found long-term endurance training increased baseline MOTS-c in both serum and muscle, and MOTS-c levels correlated with VO2max. It's both an exercise response and an exercise amplifier.
Bone and the postmenopausal angle. MOTS-c has shown protection against ovariectomy-induced osteoporosis in mice via the AMPK pathway, and prevents the weight gain and insulin resistance that follows surgical menopause in animal models. This matters because the postmenopausal metabolic shift, sudden weight gain, visceral fat redistribution, drop in insulin sensitivity, is mechanistically the population MOTS-c targets best. There are no completed human trials in postmenopausal women yet, but the preclinical signal is one of the strongest in the literature.
Pancreatic beta cells. A 2025 paper showed MOTS-c reduces senescence in pancreatic beta cells across three different mouse models of diabetes, suggesting it may slow the progressive beta cell failure that drives type 2 diabetes over time, not just improve insulin action.
The sex difference issue. This is the most important caveat in the MOTS-c literature, and most peptide guides skip it entirely. Multiple animal studies have found that the metabolic benefits of MOTS-c are more pronounced in male mice than in pre-menopausal female mice. Circulating MOTS-c levels are reduced in obese male children but not in obese female children, suggesting endogenous regulation differs by sex. The leading hypothesis is that estrogen is already activating many of the same downstream pathways MOTS-c works through (AMPK, mitochondrial biogenesis, GLUT4), so cycling pre-menopausal women have less metabolic headroom for MOTS-c to add on top. The two contexts where MOTS-c does work well in females are after ovariectomy (estrogen withdrawal) and in metabolically challenged states. Practically, if you're a cycling pre-menopausal woman with normal metabolic markers, expect a smaller effect than the male data suggests. If you're peri- or postmenopausal, or insulin-resistant, the mechanistic argument is stronger.
The K14Q variant. A naturally occurring East Asian-specific MOTS-c variant (K14Q) doesn't bind CK2 properly and produces a weaker insulin-sensitizing effect. Male carriers have higher rates of type 2 diabetes and sarcopenia, especially when sedentary, while female carriers have age-specific reduced T2D risk. This is genetic evidence that MOTS-c signaling is functionally important for human metabolic health, not just a lab curiosity.
Limitations of the evidence. Almost everything above is animal data. The only human clinical trial of a MOTS-c-based therapeutic is CohBar's Phase 1 trial of CB4211, an analog (not native MOTS-c). That trial showed CB4211 was safe and well tolerated in 7 days of dosing, with persistent injection-site bumps as the main issue, and showed signals of glucose lowering and trending weight loss in obese participants over 28 days. Sample size was 20. Native MOTS-c has not been tested in a completed human trial. There is no validated dose, no validated cycle length, no long-term safety data, and no human efficacy data for fat loss or exercise performance specifically. Everything in the dosing section below is extrapolated from animal models, the CB4211 trial, and clinic-reported protocols, not from established human evidence.
The cancer caveat. The same AMPK and angiogenesis-adjacent mechanisms that make MOTS-c metabolically useful create theoretical concern around active cancer. Some preclinical work suggests MOTS-c may have anti-tumor effects (a 2024 paper showed it suppresses ovarian cancer progression), but other work raises concerns about prostate and breast cancer growth. Until human safety data exists, anyone with an active cancer diagnosis or recent history should avoid it.

Dosage:

  • Standard subcutaneous dose: 5-10 mg per week, typically split into 2-3 injections of 2-5 mg each. The most common protocol is 5 mg twice weekly for 4-8 weeks. Inject into abdomen or thigh, rotate sites
  • Cycle length: 4-8 weeks on, 4 weeks off. Don't run continuously. AMPK signaling can downregulate with chronic stimulation and there's no human data on cycles past 8 weeks. Older adults and metabolically compromised users tend to respond better to longer (8-week) cycles, healthy users can do shorter ones
  • Timing: Morning injection is the default because users often report a noticeable energy lift within the first hour and you don't want it disrupting sleep. Take it before training on workout days, the data suggests MOTS-c and exercise synergize on the AMPK/PGC-1u03b1 pathway rather than just stack additively
  • Reconstitution: Standard with bacteriostatic water, MOTS-c is less stable than most peptides once in solution, use within 7-10 days.
  • Stacking: Combines logically with caloric deficit training, GLP-1 agonists (separate mechanisms, both improve glucose disposal), and standard recomp peptides. Avoid stacking with metformin or berberine without monitoring, all three activate AMPK and the combination is understudied

Here's what you can expect:

The most consistent subjective effect users report in the first 1-2 weeks is a small uptick in energy and exercise tolerance, you can push slightly harder in the gym or feel less wiped after a hard session. By weeks 2-4, fat loss starts becoming visible, especially around the midsection, and people who track their fasting glucose or CGM often see a small downward shift in baseline numbers. Recovery between sessions tends to feel cleaner.
Weeks 4-8 are where the more durable changes show up. Endurance and stamina improve more noticeably, body composition shifts (less fat, often slightly more muscle quality without obvious mass gain), and metabolic markers if you bloodwork them tend to look better, fasting insulin lower, HbA1c trending down if it was elevated.
If you're metabolically healthy, lean, and well-trained going in, you may notice very little. MOTS-c works best as a corrective on a system that's drifted, less as an enhancer on a system that's already optimized. This is the most common reason people describe it as "didn't feel anything," they didn't have the metabolic stress for it to act on.

Side effects & risks:

  • Injection site reactions are the most common issue, redness, mild swelling, or small painless lumps that can persist for days to weeks. The CB4211 Phase 1 trial was actually paused once because of persistent injection-site bumps. Rotating sites and using fresh needles helps. Some users get less reaction switching between abdomen and thigh
  • Mild fatigue or lethargy in the first week as cells shift toward fat oxidation. Usually resolves. If it persists, drop the dose
  • Hunger or appetite changes can go either way, some people get appetite suppression, others get more hungry from increased fat mobilization. Both are normal
  • Mild headache in the first few injections is reported, mechanism unclear, usually resolves
  • Cancer risk is the most important caution. Avoid completely with active cancer diagnosis or recent history (within 5 years). The growth and angiogenic mechanisms are theoretical concerns and human safety data doesn't exist to rule them in or out. Particularly with prostate and breast cancer history, the signal is mixed enough to err on the side of avoidance
  • Hypoglycemia risk if combined with insulin, sulfonylureas, or aggressive carb restriction. MOTS-c improves glucose disposal, stacking it with anything that drops glucose hard requires monitoring
  • WADA banned (peptide hormones, growth factors and related substances, S2 category). If you're tested in or out of competition, this will fail you
  • No long-term human safety data exists. Beyond 28 days no human cohort has been studied. Cycle conservatively. Don't run multiple back-to-back cycles without a break
  • Source quality matters more than for most peptides. MOTS-c is sold almost entirely as research-grade, no pharmaceutical-grade product is available outside clinical trials. Verify with a third-party COA before using
  • Avoid in pregnancy and breastfeeding. No safety data
🩸

Blood markers

Fasting glucose, fasting insulin, HOMA-IR, HbA1c, baseline before starting and at 8-12 weeks. These are the markers MOTS-c is mechanistically designed to move. If you don't see improvement here over a cycle, the protocol isn't working for you regardless of how you feel.
Full lipid panel (LDL, HDL, triglycerides, ApoB), baseline and at end of cycle. AMPK activation generally improves lipid handling, this is where you'd see secondary metabolic benefit.
ALT, AST, GGT (liver enzymes), baseline and end of cycle. Particularly relevant if you're running MOTS-c for fatty liver, which is one of the strongest preclinical use cases. The CB4211 trial showed liver enzyme reductions in obese participants with elevated baseline liver fat.
CBC and basic metabolic panel, baseline. Standard hygiene before starting any injectable peptide.
For PSA in men over 40 and standard breast screening in women, stay current on age-appropriate cancer screening before and during use, given the unresolved theoretical concerns.
For most users, fasting glucose, insulin, HOMA-IR, HbA1c, and a full lipid panel before and after a cycle is the minimum useful workup.
MOTS-c is sold as a research-use-only peptide and is not approved for human therapeutic use in any jurisdiction. Banned by WADA.